Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CombinaiR3 - First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years

NCT03011528 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT03011528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03011528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CombinaiR3 - First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
November 30, 2023
Enrollment
45 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma family of tumors